Key result
Failing single-ventricle hearts exhibit dysregulated metabolism and impaired mitochondrial function versus nonfailing hearts.
Why the study?
The mechanisms responsible for heart failure in single-ventricle congenital heart disease are unknown.
Observational
Metabolic therapies merit exploration in single-ventricle failure; leaves open whether CPT modulation alters outcomes.
The mechanisms responsible for heart failure in single-ventricle congenital heart disease are unknown. Using explanted heart tissue, we showed that failing single-ventricle hearts have dysregulated metabolic pathways, impaired mitochondrial function, decreased activity of carnitine palmitoyltransferase activity, and altered functioning of the tricarboxylic acid cycle. Interestingly, nonfailing single-ventricle hearts demonstrated an intermediate metabolic phenotype suggesting that they are vulnerable to development of heart failure in the future. Mitochondrial targeted therapies and treatments aimed at normalizing energy generation could represent a novel approach to the treatment or prevention of heart failure in this vulnerable group of patients.
No takes yet. Share an insight, caveat, or question.
Garcia et al. (2023) conducted an observational in Single-ventricle congenital heart disease. Failing single-ventricle hearts vs. Nonfailing single-ventricle hearts was evaluated on Metabolic pathways, mitochondrial function, and carnitine palmitoyltransferase activity. Failing single-ventricle hearts exhibited dysregulated metabolic pathways, impaired mitochondrial function, and decreased carnitine palmitoyltransferase activity compared to nonfailing hearts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: